SG77569A1 - Melatonin derivatives for use in treating desynchronization disorders - Google Patents

Melatonin derivatives for use in treating desynchronization disorders

Info

Publication number
SG77569A1
SG77569A1 SG1996008484A SG1996008484A SG77569A1 SG 77569 A1 SG77569 A1 SG 77569A1 SG 1996008484 A SG1996008484 A SG 1996008484A SG 1996008484 A SG1996008484 A SG 1996008484A SG 77569 A1 SG77569 A1 SG 77569A1
Authority
SG
Singapore
Prior art keywords
melatonin derivatives
desynchronization disorders
treating
treating desynchronization
disorders
Prior art date
Application number
SG1996008484A
Other languages
English (en)
Inventor
Michael Edward Flaugh
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SG77569A1 publication Critical patent/SG77569A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG1996008484A 1993-11-18 1994-11-16 Melatonin derivatives for use in treating desynchronization disorders SG77569A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/154,903 US6180657B1 (en) 1993-11-18 1993-11-18 Melatonin derivatives for use in treating desynchronization disorders

Publications (1)

Publication Number Publication Date
SG77569A1 true SG77569A1 (en) 2001-01-16

Family

ID=22553300

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996008484A SG77569A1 (en) 1993-11-18 1994-11-16 Melatonin derivatives for use in treating desynchronization disorders

Country Status (21)

Country Link
US (1) US6180657B1 (de)
EP (1) EP0656209B1 (de)
JP (1) JPH07196504A (de)
KR (1) KR950013509A (de)
CN (1) CN1100533C (de)
AT (1) ATE239470T1 (de)
AU (1) AU7777694A (de)
CA (1) CA2135710C (de)
CZ (1) CZ288834B6 (de)
DE (1) DE69432626T2 (de)
DK (1) DK0656209T3 (de)
ES (1) ES2197904T3 (de)
HU (1) HUT72070A (de)
IL (1) IL111579A (de)
NO (1) NO307364B1 (de)
NZ (1) NZ264893A (de)
PT (1) PT656209E (de)
RU (1) RU2160101C2 (de)
SG (1) SG77569A1 (de)
UA (1) UA35588C2 (de)
ZA (1) ZA948928B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0748627A3 (de) * 1995-06-14 1997-05-21 Lilly Co Eli Melatoninagonisten zur Behandlung von gutartigen Hyperplasieformen der Prostata
CA2551117A1 (en) * 2003-12-23 2005-07-14 Abraxis Bioscience, Inc. Substituted melatonin derivatives, process for their preparation, and methods of use
AR061478A1 (es) * 2006-06-19 2008-08-27 Takeda Pharmaceutical Compuesto triciclico y composicion farmaceutica
CA2724782A1 (en) * 2008-05-19 2009-11-26 Takeda Pharmaceutical Company Limited An anti-cancer cytotoxic monoclonal antibody
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
KR20180100450A (ko) 2012-01-26 2018-09-10 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
MX2015007909A (es) 2012-12-18 2016-04-25 Vanda Pharmaceuticals Inc Tratamiento de trastornos del ritmo circadiano.
RU2533965C1 (ru) * 2013-07-04 2014-11-27 Государственное бюджетное учреждение здравоохранения "Самарский областной гериатрический центр" Способ нормализации циркадианных ритмов человека
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
RU2655813C1 (ru) * 2017-06-09 2018-05-29 Федеральное государственное бюджетное учреждение науки "Институт токсикологии Федерального медико-биологического агентства" Средство коррекции и профилактики состояний, вызванных нарушением суточных ритмов

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087444A (en) 1976-09-08 1978-05-02 Eli Lilly And Company Amides as ovulation inhibitors
US4600723A (en) 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
EP0126630B1 (de) * 1983-05-18 1987-09-16 Monash University Verwendung von Melatonin zur Herstellung eines Arzneimittels
US4614807A (en) 1984-10-04 1986-09-30 Eli Lilly And Company 6,7-dihalomelatonins
US4687763A (en) 1985-02-25 1987-08-18 Massachusetts Institute Of Technology Composition and method for increasing levels or release of brain serotonin
IL79264A0 (en) 1986-06-27 1986-09-30 Univ Ramot Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
US4997845A (en) 1987-02-02 1991-03-05 Eli Lilly And Company β-alkylmelatonins as ovulation inhibitors
WO1989001472A1 (en) 1987-08-17 1989-02-23 Nelson Research & Development Co. Melatonin analogues
US5093352A (en) 1988-11-14 1992-03-03 Whitby Research, Inc. Antidepressant agents
JPH0418034A (ja) * 1990-05-11 1992-01-22 Kanegafuchi Chem Ind Co Ltd 点眼組成物
US5242941A (en) 1990-12-04 1993-09-07 State Of Oregon Methods of treating circadian rhythm disorders
IT1251544B (it) 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
ZA928011B (en) * 1991-10-18 1993-06-23 Alza Corp Transdermal administration of melatonin.
US5196435A (en) 1991-11-21 1993-03-23 Eli Lilly And Company Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma
IT1254995B (it) * 1992-06-24 1995-10-11 Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani
IT1255199B (it) * 1992-07-01 1995-10-20 Franco Fraschini Farmaco sintetizzato analogo della melatonina particolarmente efficacenelle patologie che interferiscono con i ritmi circadiani
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin

Also Published As

Publication number Publication date
DK0656209T3 (da) 2003-09-01
PT656209E (pt) 2003-09-30
NO307364B1 (no) 2000-03-27
CZ276494A3 (en) 1995-07-12
HU9403299D0 (en) 1995-01-30
IL111579A (en) 1999-10-28
NZ264893A (en) 1997-06-24
EP0656209A3 (de) 1995-10-11
DE69432626D1 (de) 2003-06-12
ATE239470T1 (de) 2003-05-15
CA2135710C (en) 2007-07-10
NO944340D0 (no) 1994-11-14
CZ288834B6 (cs) 2001-09-12
HUT72070A (en) 1996-03-28
RU94041028A (ru) 1996-09-20
IL111579A0 (en) 1995-01-24
CN1100533C (zh) 2003-02-05
CA2135710A1 (en) 1995-05-19
EP0656209B1 (de) 2003-05-07
AU7777694A (en) 1995-05-25
UA35588C2 (uk) 2001-04-16
JPH07196504A (ja) 1995-08-01
CN1107700A (zh) 1995-09-06
NO944340L (no) 1995-05-19
DE69432626T2 (de) 2004-04-08
RU2160101C2 (ru) 2000-12-10
US6180657B1 (en) 2001-01-30
ES2197904T3 (es) 2004-01-16
EP0656209A2 (de) 1995-06-07
ZA948928B (en) 1996-05-10
KR950013509A (ko) 1995-06-15

Similar Documents

Publication Publication Date Title
HU0301601D0 (en) Bis(n-substituted)-staurosporine derivatives, their use and pharmaceutical composition containing thereof
NZ332780A (en) Substituted amines for the treatment of neurological and neuropsychiatric disorders
IL107248A0 (en) Apparatus for treatment of the oral cavity
EP0651650A4 (de) METHODE ZUR BEHANDLUNG VON AUGENKRANKHEITEN MITTELS TGF--g(b).
IL101056A0 (en) Composition for nasal treatment
GB2146527B (en) Use of benzothiophene derivatives as antiasthmatic agents
SG77569A1 (en) Melatonin derivatives for use in treating desynchronization disorders
SG50505A1 (en) Melatonin derivatives for use in treating sleep disorders
IL105957A0 (en) Handpiece for laser apparatus
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
IL105475A0 (en) Pharmaceutical compositions containing 1alpha,24(r)-dihydroxy-22(e)-dehydro-vitamin d3 for treating osteoporosis
EP0729734A3 (de) Laserbehandlungsvorrichtung
RU2004219C1 (ru) Устройство дл выт жени шейного отдела позвоночника
AU4973690A (en) Apparatus for treatment of disorders
AU8854891A (en) Laser apparatus for periodontal treatment
GB9226059D0 (en) Apparatus for medical treatment
HU9500620D0 (en) Soft laser apparatus for medical therapy